Sutro Biopharma opened lower at $10.01, compared with its previous close of $10.26. In the last trading session, the stock traded between $9.20 and $10.12. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Sutro Biopharma is now worth
$ 4.69
Resulting in a loss of
$ 95.31 (95.31%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 7 Analysts
Buy
85.71%
Hold
0%
Sell
14.29%
Markets Today
Today's Change
$-0.68 (-6.64%)
Day High
$10.12
Day Low
$9.20
Day Open
$10.01
Prev Close
$10.26
Volume
6,30,871
1W Return
-3.74%
1M Return
-27.80%
3M Return
-61.79%
6M Return
-75.63%
1Y Return
17.81%
Fundamentals
Market Cap ($ Mn)
159
PE Ratio
-
PB Ratio
-
PEG Ratio
-
ROE
-
ROCE
-91.20%
EPS (TTM)
$-2.32
Investment Returns
1 Week
-3.74%
1 Month
-27.80%
3 Months
-61.79%
6 Months
-75.63%
9 Months
-39.10%
Financials
Quarterly
All values in $ Mn
17.4
Mar 25
63.7
Jun 25
9.7
Sep 25
11.6
Dec 25
14.5
Mar 26
9.8
Jun 26
Updates
21Oct
Sutro Biopharma doses first patient in Phase 1 trial of STRO-006
First patient dosed in Phase 1 trial for STRO-006, an ITGB6-targeting ADC. Initial clinical data expected in H2 2027. Starting dose set at 1.5 mg/kg based on non-human primate tolerability data. Trial targets seven solid tumor types including lung and breast cancer.
22 days ago
15Oct
Wedbush reiterates Outperform on Sutro Biopharma, holds $60 target
Wedbush analyst David Nierengarten reiterated an Outperform rating. Price target maintained at $60 per share. No change in investment thesis or valuation metrics disclosed.
28 days ago
13Aug
Sutro Biopharma stock falls 24% after STRO-004 Phase 1 update
Sutro Biopharma stock fell 24.46% to $18.91 after reporting dose-limiting toxicities at the highest dose level in its STRO-004 Phase 1 study. Despite the setback, the company holds $164.3 million in cash, supporting operations into Q2 2028. Analysts maintain a Buy consensus with an average target of $48.00.
3mo ago
11Jun
Truist Securities initiates Sutro Biopharma coverage with Buy rating
Truist Securities analyst Supawat Thongthip has initiated coverage on Sutro Biopharma with a Buy rating and a price target of $50.
